Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 4 study of repeat-dose rimegepant for acute treatment of migraine in adults
CTR20263735Phase 4Active
- Sponsor
- Pfizer
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rimegepant in migraine, sponsored by Pfizer. Started Jun 2026; status: active.
02
Drugs
rimegepant
03
Conditions
migraine
Beyond the preview
Go deeper on CTR20263735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263735.